Enliven Therapeutics, Inc. annual report, FY2022

Business context and reporting period

This is IMARA Inc.’s Form 10-K for the fiscal year ended December 31, 2022, filed February 10, 2023—not a standalone fourth-quarter report. The filing concerns IMARA, which had agreed to merge with Enliven Therapeutics; it does not report Enliven’s standalone financial results. If completed, Enliven’s business was expected to become the combined company’s business.

IMARA discontinued development of all its programs in April 2022, completed the sale of its tovinontrine/PDE9 assets to Cardurion in November, and reported no active research and development or product candidates at year-end.

Financial results and position

2022 net income reflected the $35.0 million asset-sale gain; excluding that gain, operating expenses were $34.3 million and the company remained loss-making from operations. No meaningful product gross margin was reported. Interest income was $0.9 million, versus $0.2 million in 2021.

At December 31, 2022, cash and cash equivalents were $88.2 million, with no short-term investments. Total assets were $92.0 million; total liabilities were $1.8 million, consisting principally of accounts payable and accrued liabilities. There was no reported debt balance. Accumulated deficit was $146.0 million. Management believed available cash would fund operating expenses and capital requirements for at least 12 months from the filing date, subject to assumptions that might prove incorrect.

Cash increased by $39.7 million during 2022. Investing activities provided $76.5 million, including $35.0 million of asset-sale proceeds and $41.9 million from investment maturities and sales. Financing activities used $1.2 million, primarily for transaction costs.

Material changes versus the prior comparable period

• R&D expense fell $19.5 million, primarily after program discontinuations and workforce reductions; G&A expense rose $2.3 million, including legal and professional costs related to the asset sale and strategic process.
• Net results shifted from a $51.4 million loss in 2021 to $1.5 million of income in 2022, principally because of the asset-sale gain—not product revenue or recurring operating profitability.
• Cash and cash equivalents increased from $48.3 million to $88.2 million, while short-term investments declined from $42.0 million to zero.
• IMARA ended its office lease in August 2022, reported no lease liabilities at year-end, and had six full-time employees at December 31.

Outlook, risks and unusual items

The Cardurion asset sale provided $34.75 million at closing, in addition to $0.25 million paid earlier. Potential additional payments of $10 million for clinical milestones and $50 million for regulatory or commercial milestones were contingent and not included in the recognized transaction price.

The proposed Enliven merger remained subject to conditions as of the filing, including IMARA stockholder approval, the required Enliven financing, Nasdaq listing approval, and IMARA net cash within the agreement’s $75–$95 million range. Enliven stockholders had approved the merger, the SEC had declared the registration statement effective, the antitrust waiting period had expired, and the asset sale had closed. The financing was described as approximately $164.5 million. Expected ownership was approximately 84.1% for pre-merger Enliven holders and 15.9% for pre-merger IMARA holders, subject to the agreement’s terms and adjustments.

If the merger failed, IMARA said it could pursue another transaction, resume operations and seek product candidates, or dissolve and liquidate. A liquidation distribution to stockholders was uncertain and would depend on obligations, reserves, timing, and costs. Specified merger termination circumstances could require IMARA to pay Enliven a $3.0 million fee. Pre-merger holders were expected to receive contingent value rights tied to possible future proceeds from the asset sale; there was no assurance of payment.

Key risks include the merger not closing or not producing expected benefits, cash running down during a delay or liquidation, inability to secure financing if development resumes, and the lack of an active pipeline or revenue source. IMARA reported that disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not provide an internal-control attestation.

Important facts for investors to verify

• Confirm the merger’s eventual closing, final financing proceeds, closing cash calculation, exchange ratio, reverse split, and ownership dilution; these were not final in this 10-K.
• Review the Cardurion agreement and CVR terms, including whether milestone conditions are achieved and whether any CVR payments become payable.
• Assess cash burn and runway against actual post-year-end spending; the stated runway was management’s estimate, not a guarantee.
• Distinguish the one-time asset-sale gain from recurring operating performance; IMARA reported no product revenue and had discontinued development activities.
• Check subsequent filings for changes in strategy, workforce, contingent obligations, and merger-related costs or termination fees.